Literature DB >> 29908671

New-generation JAK inhibitors: how selective can they be?

Guro L Goll1, Tore K Kvien2.   

Abstract

Mesh:

Substances:

Year:  2018        PMID: 29908671     DOI: 10.1016/S0140-6736(18)31325-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.

Authors:  Alain Lescoat; John Varga; Marco Matucci-Cerinic; Dinesh Khanna
Journal:  Expert Opin Investig Drugs       Date:  2021-05-13       Impact factor: 6.498

2.  Renal expression of JAK2 is high in polycystic kidney disease and its inhibition reduces cystogenesis.

Authors:  Foteini Patera; Alex Cudzich-Madry; Zhi Huang; Maria Fragiadaki
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

3.  A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing γc cytokine-related JAK-STAT signal.

Authors:  Chengjuan Chen; Yuan Yin; Gaona Shi; Yu Zhou; Shuai Shao; Yazi Wei; Lei Wu; Dayong Zhang; Lan Sun; Tiantai Zhang
Journal:  Sci Adv       Date:  2022-08-19       Impact factor: 14.957

Review 4.  An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years.

Authors:  Corrado Campochiaro; Yannick Allanore
Journal:  Arthritis Res Ther       Date:  2021-06-01       Impact factor: 5.156

5.  Genome profiling revealed the activation of IL2RG/JAK3/STAT5 in peripheral T‑cell lymphoma expressing the ITK‑SYK fusion gene.

Authors:  Lei-Lei Zhang; Hua-Xiong Pan; Yi-Xuan Wang; Tao Guo; Lin Liu
Journal:  Int J Oncol       Date:  2019-09-20       Impact factor: 5.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.